Reshaping the Future of Nanopharmaceuticals: Ad Iudicium

被引：75

作者：

Moghimi, S. Moein ^{[1
]}

Peer, Dan ^{[2
,3
]}

Langer, Robert ^{[4
,5
]}

机构：

[1] Univ Copenhagen, Ctr Pharmaceut Nanotechnol & Nanotoxicol, DK-2100 Copenhagen O, Denmark

[2] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, Lab Nanomed, IL-69978 Tel Aviv, Israel

[3] Tel Aviv Univ, Ctr Nanosci & Nanotechnol, IL-69978 Tel Aviv, Israel

[4] MIT, Dept Chem Engn, Cambridge, MA 02139 USA

[5] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA

来源：

ACS NANO | 2011年 / 5卷 / 11期

关键词：

SIRNA DELIVERY; COMPLEMENT ACTIVATION; NANOPARTICLES; CANCER; CYTOTOXICITY; COMPETITION; INNOVATION; BIOLOGICS; PLATFORM; THERAPY;

D O I：

10.1021/nn2038252

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

We present views on the future development of biologics-based nanopharmaceuticals from a "high risk high gain" perspective and within the context of personalized therapies. Integrated scientific, commercial, and societal aspects are addressed, and provocative combined realistic biotech, computational, and nanotech approaches for tailor-made engineering of nanopharmaceuticals are discussed.

引用

页码：8454 / 8458

页数：5

共 29 条

[1] Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers) [J].

Ahmadvand, Davoud ;

Rahbarizadeh, Fatemeh ;

Moghimi, Seyed Moein .

CURRENT OPINION IN BIOTECHNOLOGY, 2011, 22 (06) :832-838

[2] An Integrated Approach to Uncover Drivers of Cancer [J].

Akavia, Uri David ;

Litvin, Oren ;

Kim, Jessica ;

Sanchez-Garcia, Felix ;

Kotliar, Dylan ;

Causton, Helen C. ;

Pochanard, Panisa ;

Mozes, Eyal ;

Garraway, Levi A. ;

Pe'er, Dana .

CELL, 2010, 143 (06) :1005-1017

[3] Nonviral delivery of synthetic siRNAs in vivo [J].

Akhtar, Saghir ;

Benter, Ibrahim F. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) :3623-3632

[4] Drug delivery systems: Entering the mainstream [J].

Allen, TM ;

Cullis, PR .

SCIENCE, 2004, 303 (5665) :1818-1822

[5]

[Anonymous], 2004, Nature, V428, P239

[6]

[Anonymous], 2010, Health at a Glance: Europe 2010

[7] Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals [J].

Blackstone, Erwin A. ;

Fuhr, Joseph P., Jr. .

FUTURE MEDICINAL CHEMISTRY, 2010, 2 (11) :1641-1649

[8] On firm ground: IP protection of therapeutic nanoparticles [J].

Burgess, Paul ;

Hutt, Peter Barton ;

Farokhzad, Omid C. ;

Langer, Robert ;

Minick, Scott ;

Zale, Stephen .

NATURE BIOTECHNOLOGY, 2010, 28 (12) :1267-1271

[9] Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles [J].

Dhar, Shanta ;

Gu, Frank X. ;

Langer, Robert ;

Farokhzad, Omid C. ;

Lippard, Stephen J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (45) :17356-17361

[10] Immunological properties of engineered nanomaterials [J].

Dobrovolskaia, Marina A. ;

Mcneil, Scott E. .

NATURE NANOTECHNOLOGY, 2007, 2 (08) :469-478

← 1 2 3 →